Core Insights - 康臣药业 reported a net profit attributable to equity shareholders of 910 million RMB for the year ending December 31, 2024, representing a year-on-year increase of 16.05% [1] - The company's total revenue reached 2.967 billion RMB, marking a 14.56% increase compared to the previous year [1] - The company plans to distribute a final dividend of 0.3 HKD per share [1] Revenue Breakdown - The renal product series achieved a sales growth of approximately 14.6%, with尿毒清颗粒 remaining the flagship product [2] - The pediatric and women's health product series saw a notable sales increase of about 23.1%, becoming the second-largest revenue contributor [2] - Sales of medical imaging contrast agents grew by approximately 9.0% year-on-year [2] - The orthopedic product series experienced a significant sales increase of 64.9% [2] - Sales in the dermatology product series declined by 9.5%, while the hepatobiliary product series saw a decrease of 40.0% [2] - Other pharmaceuticals experienced a decline in sales of 39.2% [2] Strategic Developments - In 2024, the company completed the consistency evaluation approval for four specifications of gadopentetate dimeglumine injection and received approval for iodinated contrast agent injection [2] - The company submitted a listing application for perfluoropropane lipid microspheres and completed production verification for gadobutrol injection, pending listing application [2] - The company published four SCI papers, enhancing the clinical application safety of its renal products [2]
康臣药业(01681)发布年度业绩 权益股东应占溢利9.1亿元 同比增加16.05%